PMGC Holdings Inc.
NCM: ELABLive Quote
📈 ZcoreAI Score
Our AI model analyzes PMGC Holdings Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get ELAB Z-Score →About PMGC Holdings Inc.
Healthcare
Biotechnology
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operates investment firms. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.
📊 Fundamental Analysis
PMGC Holdings Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -107.3%, which indicates that capital utilization is currently under pressure.
At a current price of $4.79, ELAB currently trades near the bottom of its 52-week range (1%), indicating potential value or weakness (Range: $1.62 - $309.89).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$9.28M
Trailing P/E
--
Forward P/E
--
Beta (5Y)
0.71
52W High
$309.89
52W Low
$1.62
Avg Volume
7.22M
Day High
Day Low